<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687255</url>
  </required_header>
  <id_info>
    <org_study_id>AT-301</org_study_id>
    <nct_id>NCT03687255</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allecra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allecra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, randomized, double-blind, non-inferiority study of cefepime 2 g/AAI101 500 mg
      combination compared to piperacillin 4 g/tazobactam 500 mg in a population of adult patients
      with cUTI or AP. The study will be conducted in approximately 115 sites located in the EU,
      the US, Central, South America and South Africa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">February 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in the Microbiological Modified Intent to Treat (m-MITT) Population who achieve overall treatment success at Test Of Cure (TOC)</measure>
    <time_frame>7 days after EOT [±2 days] for patients receiving 7 days of treatment and 19 days after randomization [±2 days] for patients receiving more than 7 days of treatment.</time_frame>
    <description>Treatment success is defined as the composite of clinical outcome of Cure and the microbiological outcome of Eradication (&lt;103 CFU/mL in urine culture).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the m-MITT Population with overall treatment success at End of Treatment (EOT)</measure>
    <time_frame>7 days for patients with cUTI only and up to 14 days for patients cUTI and blood stream infections</time_frame>
    <description>Treatment success is defined as the composite of clinical outcome of Cure and the microbiological outcome of Eradication (&lt;103 CFU/mL in urine culture).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1043</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>cefepime/AAI101 combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefepime 2 g in combination with AAI101 500 mg q8h (2 hour infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piperacillin 4 g in combination with Tazobactan 500 mg q8h (2 hour infusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime/AAI101 combination</intervention_name>
    <description>cefepime 2 g / AAI101 500 mg</description>
    <arm_group_label>cefepime/AAI101 combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/tazobactam</intervention_name>
    <description>piperacillin 4 GM / tazobactam 500 MG</description>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <other_name>PIP/TAZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male or female patients &gt;18 years of age at the time of signing of informed consent;

          2. Expectation that the patient's cUTI or AP will require hospitalisation and initial
             treatment with at least 7 days of intravenous (i.v.) antibiotics;

          3. Female patients who are no longer of childbearing potential

          4. Female patients of childbearing potential must have a negative urine and/or serum
             pregnancy test (serum β-human chorionic gonadotropin) within 1 day prior to study
             entry;

          5. Male patients, female patients receiving hormone replacement therapy (HRT), and female
             patients of childbearing potential must agree to use highly effective contraception
             methods

          6. Pyuria, defined as: a. White blood cell count &gt;10 cells/mm3 in unspun urine or ≥10
             cells/high power field in spun urine sediment; or b. Urinalysis/dipstick analysis
             positive for leukocyte esterase;

          7. Clinical signs and/or symptoms of cUTI or AP

          8. Have a baseline urine culture specimen obtained within 48 hours prior to randomization

          9. Expectation, in the judgment of the Investigator, that any implanted urinary
             instrumentation (e.g., nephrostomy tubes, ureteric stents, etc.) will be surgically
             removed or replaced before or within 24 hours after randomisation, unless removal or
             replacement is considered unsafe or contraindicated.

        Exclusion Criteria

          1. Known urine culture with Gram-positive primary pathogen at ≥105 colony-forming units
             (CFU)/mL (not contaminant) or suspected Gram-positive pathogen by Gram staining (Note:
             Gram staining is optional);

          2. History of significant hypersensitivity or allergic reaction to cefepime,
             piperacillin/tazobactam, any of the excipients used in the respective formulations,
             any beta-lactam antibiotics (e.g., cephalosporins, penicillins, carbapenems, or
             monobactams), or any beta-lactamase inhibitors (e.g., tazobactam, sulbactam, or
             clavulanic acid);

          3. In the opinion of the Investigator, the patient is considered unlikely to survive the
             approximately 6-week study period;

          4. Weight &gt;180 kg;

          5. Concurrent infection that would interfere with evaluation of response to the study
             antibiotics;

          6. Need for or receipt of concomitant systemic antimicrobial agents after signing of
             informed consent, in addition to those designated in the study-treatment groups, with
             the exception of a single oral dose of any antifungal treatment for vaginal
             candidiasis;

          7. Receipt of potentially effective systemic antibacterial therapy for a continuous
             duration of &gt; 24 hours during the previous 72 hours before the study-qualifying
             baseline urine is obtained;

          8. Complicated urinary tract infection (UTI) known at study entry to be caused by
             pathogens resistant to the study antibiotics;

          9. Likely to require the use of an antibiotic for cUTI or AP prophylaxis during the
             patient's participation in the study;

         10. Intractable UTI at baseline that the Investigator anticipates would require &gt;14 days
             of study drug therapy;

         11. Complete, permanent obstruction of the urinary tract that is not anticipated to be
             medically or surgically relieved during i.v. study therapy and before End of Treatment
             (EOT);

         12. Gross hematuria requiring intervention other than administration of study drug or
             removal or exchange of a urinary catheter;

         13. Presence of any known or suspected disease or condition that, in the opinion of the
             Investigator, may confound the assessment of efficacy.

         14. Suspected or confirmed acute bacterial prostatitis, orchitis, epididymitis, or chronic
             bacterial prostatitis as determined by history and/or physical examination;

         15. Impairment of renal function with estimated glomerular filtration rate &lt;30 mL/min/1.73
             m2 calculated by the 4-variable Modification of Diet in Renal Disease study equation,

         16. Urinary tract surgery within 7 days prior to randomisation or urinary tract surgery
             planned during the study period (except surgery required to relieve an obstruction or
             place a stent or nephrostomy prior to EOT);

         17. Any condition or circumstance that, in the opinion of the Investigator, would
             compromise the safety of the patient or the quality of study data;

         18. Any rapidly progressing disease or immediately life-threatening illness, including
             acute hepatic failure and respiratory failure;

         19. Presence of sepsis, producing life-threatening organ dysfunction

         20. A QT interval corrected using Fridericia's formula &gt;450 msec;

         21. Immunocompromising condition, including known history of acquired immune deficiency
             syndrome or known recent CD4 count &lt;200/mm3, hematological malignancy, or bone marrow
             transplantation; or immunosuppressive therapy including cancer chemotherapy,
             medications for prevention of organ transplantation rejection, or the administration
             of corticosteroids ≥20 mg of prednisone or equivalent per day administered
             continuously for &gt;14 days prior to randomisation;

         22. One or more of the following laboratory abnormalities in baseline specimens obtained
             at Screening: aspartate aminotransferase, alanine aminotransferase, alkaline
             phosphatase, or total bilirubin level &gt;3 × upper limit of normal, or current
             clinically significant liver disease, including any form of known liver cirrhosis;

         23. One or more of the following laboratory abnormalities at Screening: platelet count
             &lt;50,000/μL, absolute neutrophil count &lt;1,000/mm3, or hemoglobin &lt;8 g/dL;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Josephs Clinical Research</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southbay Pharma Research</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIGA Dr Ramon Carrillo</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1706FWM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brest Regional Hospital</name>
      <address>
        <city>Brest</city>
        <zip>224027</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Rahila Angelova AD, Pernik</name>
      <address>
        <city>Pernik</city>
        <zip>2300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital for Infectious Diseases &quot;Dr. Fran Mihaljevic&quot; Department for general infectious diseases</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unimed Adjara - Kutaisi oncological centre</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Korhaz</name>
      <address>
        <city>Gyöngyös</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uroklinika, LLC</name>
      <address>
        <city>Riga</city>
        <zip>LV-1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Siauliai caunty hospital</name>
      <address>
        <city>Šiauliai</city>
        <zip>76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Especializado en Investigación Clínica S.C.</name>
      <address>
        <city>Boca Del Río</city>
        <zip>CP. 94290</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional - Sede San Borja</name>
      <address>
        <city>Lima</city>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Center Eco-Safety</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interne oddelenie, Nemocnica Malacky, Nemocnicna a.s.</name>
      <address>
        <city>Malacky</city>
        <zip>90122</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Projects Research</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar, Department of Infectious Disease</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology</name>
      <address>
        <city>Chernihiv</city>
        <zip>14034</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

